Melbourne (Australia) – 11 April 2024. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the completion of the acquisition of radioisotope production technology firm ARTMS Inc. (ARTMS), its advanced cyclotron-based isotope production platform, manufacturing plant and stockpile of ultra-pure rare metals required for consumable target production.
ARTMS, based in Vancouver, BC (Canada), is a privately held, commercial-stage company, which specializes in the physics, chemistry and materials science of cyclotron-produced radionuclides. Its core technology platform, the QUANTM Irradiation System™ (QIS™), is a complete cyclotron-based isotope production system designed to support high efficiency, large-scale and cost-effective production of commercially important medical isotopes such as zirconium-89 (89Zr), gallium-68 (68Ga), technetium‐99m (99mTc) and copper-64 (64Cu). QIS™ is used today by many of the major manufacturing networks to optimize production of a range of medical radioisotopes.
ARTMS’ portfolio of advanced cyclotron technologies also has immediate application and differentiation in the production of future commercially important alpha-emitting, therapeutic isotopes, including actinium-225 (225Ac) and astatine-211 (211At).
The acquisition further enhances the vertical integration of Telix’s supply chain and manufacturing by providing a greater level of supply chain and regulatory control over the production of key isotopes.
Dr Christian Behrenbruch, Managing Director and Group CEO of Telix said, “ARTMS is a leader in the field of “next generation” cyclotron isotope production. This acquisition has multiple commercial, clinical and organizational synergies that are highly complementary to our commercial and clinical product portfolio. Most importantly this technology is designed to facilitate broader patient access to therapeutic and diagnostic radiopharmaceuticals through its efficient, high-yield production techniques. We are delighted to welcome the talented ARTMS team, their unique intellectual property, and highly differentiated technologies to the Telix Group of companies.”
